Soleus Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Soleus Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-450,500	Closed	-$6.92M	–	102
2025 Q1	$6.92M	Sell	450,500 -1,642,500	-78%	-$29.3M	0.5%	45
2024 Q4	$46.1M	Buy	+2,093,000	New	+$38.1M	2.9%	9
2024 Q3	–	Sell	-586,499	Closed	-$9.53M	–	106
2024 Q2	$9.53M	Sell	586,499 -2,899,941	-83%	-$44.7M	0.84%	38
2024 Q1	$49.2M	Sell	3,486,440 -2,078,000	-37%	-$26.2M	3.65%	5
2023 Q4	$58.1M	Sell	5,564,440 -487,724	-8%	-$4.55M	6.45%	1
2023 Q3	$61.7M	Buy	6,052,164 +1,802,164	+42%	+$16.8M	5.7%	3
2023 Q2	$32M	Buy	+4,250,000	New	+$34.5M	3.56%	7

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Soleus Capital Management's TEVA Position: Q2 2025 in Review

Soleus Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 450,500 shares — an estimated $6.92M sold.

Soleus Capital Management first reported a position in TEVA in Q2 2023 and held it in 7 quarters. The position peaked at $61.7M in Q3 2023. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

Soleus Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Soleus Capital Management sold 450,500 Teva Pharmaceuticals shares in Q2 2025, an estimated $6.92M.
Soleus Capital Management first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 7 quarters.
Soleus Capital Management's Teva Pharmaceuticals position peaked at $61.7M in Q3 2023.
539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.